The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
NEJ043: A phase 2 study of atezolizumab (atezo) plus bevacizumab (bev) plus carboplatin (carbo) plus paclitaxel (pac; ABCP) for previously treated patients with NSCLC harboring EGFR mutations (EGFRm).
 
Naoki Furuya
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai Pharma; Lilly; Novartis; Pfizer; Taiho Pharmaceutical
 
Satoshi Watanabe
Consulting or Advisory Role - Novartis
Speakers' Bureau - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo/UCB Japan; Lilly; Nippon Kayaku; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical
Research Funding - Boehringer Ingelheim
 
Atsushi Nakamura
Honoraria - AstraZeneca; Chugai Pharma; Kyowa Kirin; Lilly Japan; Novartis; Taiho Pharmaceutical; Thermo Fisher Scientific
 
Jun Shiihara
No Relationships to Disclose
 
Ichiro Nakachi
No Relationships to Disclose
 
Hisashi Tanaka
Honoraria - AstraZeneca; Boehringer Ingelheim; Chugai Pharma; Pfizer
 
Mika Nakao
No Relationships to Disclose
 
Koichi Minato
Honoraria - Bristol-Myers Squibb Japan; Chugai Pharma
Research Funding - Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst)
 
Masahiro Seike
Honoraria - AstraZeneca; Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo; Kyowa Kirin; Lilly; MSD K.K; Nippon Boehringer Ingelheim; Nippon Kayaku; Novartis; Ono Pharmaceutical; Taiho Pharmaceutical
Research Funding - Chugai Pharma (Inst); Lilly (Inst); MSD K.K (Inst); Nippon Boehringer Ingelheim (Inst); Nippon Kayaku (Inst); Taiho Pharmaceutical (Inst)
 
Shinichi Sasaki
No Relationships to Disclose
 
Akira Kisohara
No Relationships to Disclose
 
Susumu Takeuchi
No Relationships to Disclose
 
Ryoichi Honda
No Relationships to Disclose
 
Kei Takamura
No Relationships to Disclose
 
Hiroshi Kagamu
Honoraria - AstraZeneca/Daiichi Sankyo; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai Pharma; Lilly; MSD; Ono Pharmaceutical; Taiho Pharmaceutical
Consulting or Advisory Role - ImmuniT Research Inc.
Research Funding - Boehringer Ingelheim (Inst); Chugai Pharma (Inst); Kaken Pharmaceutical (Inst); Lilly (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst)
 
Kenichi Yoshimura
Honoraria - AstraZeneca; Boehringer Ingelheim; Chugai Pharma; Eisai; Lilly; Nihonkayaku; Novartis; Otsuka; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - BrightPath Biotheraputics; Nippon Shinyaku
 
Toshiaki Kikuchi
Honoraria - Astellas Pharma; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo; Janssen; Japan BCG Laboratory; Kyorin; Lilly; MSD; Mylan; Novartis; Ono Pharmaceutical; Pfizer; Roche; Shionogi; Taiho Pharmaceutical; Taisho Toyama Pharma; TEIJIN PHARMA
Consulting or Advisory Role - An2 Therapeutics; Janssen
Research Funding - AstraZeneca; Boehringer Ingelheim; Chugai Pharma; Daiichi Sankyo; Kyorin; Lilly; MSD; Nobelpharma; Ono Pharmaceutical; Shionogi; Taiho Pharmaceutical; TEIJIN PHARMA
 
Kunihiko Kobayashi
Speakers' Bureau - AstraZeneca; Takeda